approval
saveDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
community read0 votes
Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 2 initiationNational Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)Apr 29, 2026 · 163d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalFeb 12, 2026 · 239d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJan 27, 2026 · 255d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 19, 2025 · 324d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 14, 2025 · 329d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 6, 2025 · 337d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 2, 2022 · 1437d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJan 21, 2022 · 1722d ago
same company · ±60 days · 6
- approvalapalutamide: ERLEADA (APALUTAMIDE) — FDA approvalAug 2, 2024
- approvallazertinib mesylate: LAZCLUZE (LAZERTINIB MESYLATE) — FDA approvalAug 19, 2024
- approvalamivantamab: RYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalAug 19, 2024
- approvalapalutamide: ERLEADA (APALUTAMIDE) — FDA approvalJul 9, 2024
- approvaltalquetamab: TALVEY (TALQUETAMAB-TGVS) — FDA approvalJul 2, 2024
- approvalteclistamab: TECVAYLI (TECLISTAMAB-CQYV) — FDA approvalJul 2, 2024
🐶 often sniffed alongside
top 8- drugdaratumumab31 co-mentions · 16 sources
- drugdaratumumab + Gene Therapy31 co-mentions · 16 sources
- drugDARZALEX FASPRO30 co-mentions · 15 sources
- tagApproval30 co-mentions · 15 sources
- companyJanssen Biotech Inc15 co-mentions · 15 sources
- tagOncology2 co-mentions · 1 sources
- tagMultiple Myeloma2 co-mentions · 1 sources
- companyNational Cancer Institute US1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that